American Heart Association documents commitment to boost heart and stroke-related open public policy – – An American Heart Association paper underscores the necessity for policy interventions to improve health insurance and reduce loss of life from heart disease and stroke. – – The paper highlights specific policy recommendations to improve quality of treatment and the environment to promote healthful behaviors here . The American Heart Association offers, for the very first time, published a statement, American Center Association and non-profit Advocacy: Recent, Present, and Upcoming, that papers the association’s longstanding commitment to improve heart and stroke-related public policy.

Ambit Biosciences presents data from Stage 2 ACE study of quizartinib for treatment of AML Ambit Biosciences Corporation announced today data from the Phase 2 ACE study of quizartinib , a FLT3 inhibitor, were featured in multiple presentations at the 18th Congress of the European Hematology Association in Stockholm, Sweden. Data presented included analyses of patients with relapsed or refractory acute myeloid leukemia from a Phase 2 medical trial of quizartinib as monotherapy. In the scholarly study, quizartinib orally was administered, once a day, in 28-day time treatment cycles until disease progression, elective hematopoietic stem cell transplantation or unacceptable toxicity.